What are the outcomes of smoking during radiotherapy for prostate cancer?

Smoking During Radiotherapy for Prostate Cancer: Outcomes

Patients who smoke during radiotherapy for prostate cancer experience significantly worse treatment efficacy and substantially increased long-term toxicity, particularly severe genitourinary complications affecting the bowel and anal sphincter—making smoking cessation before and during treatment a critical intervention to improve both survival and quality of life.

Impact on Cancer Control and Mortality

According to NCCN guidelines, active smoking may decrease the efficacy of radiotherapy for prostate cancers 1. The evidence demonstrates:

• Current smokers have a 2.25-fold increased risk of prostate cancer-specific death after definitive radiotherapy 2
• Biochemical recurrence risk increases by 40% (hazard ratio 1.4) in current smokers 2
• Distant metastasis risk more than doubles (hazard ratio 2.37) among active smokers during treatment 2

These findings represent high-quality research from a large cohort of 2,156 patients with median follow-up of 95 months, demonstrating clear dose-dependent effects on disease control 2.

Treatment-Related Toxicity

Genitourinary Complications

The most clinically significant impact of smoking during prostate radiotherapy is dramatically increased long-term genitourinary toxicity:

• Current smokers have an 80% increased risk of genitourinary toxicity (hazard ratio 1.8) 2
• Former smokers retain a 45% elevated risk even after cessation (hazard ratio 1.45) 2
• Current smokers face a 3-fold increased risk of severe grade ≥3 genitourinary toxicity 3

This toxicity persists regardless of smoking quantity or duration of exposure 2, suggesting even light smoking is harmful during treatment.

Bowel and Anal Sphincter Effects

NCCN guidelines specifically highlight that smoking increases the prevalence of long-lasting treatment-related effects on the bowel and anal sphincter 1. Detailed research reveals:

• Defecation urgency increases 60% (prevalence ratio 1.6) in current smokers 4
• Diarrhea risk nearly triples (prevalence ratio 2.8) 4
• Fecal incontinence (sudden uncontrolled bowel movements) increases nearly 5-fold (prevalence ratio 4.7) 4
• Sensation of incomplete bowel emptying doubles (prevalence ratio 2.1) 4

These symptoms persist long-term, assessed at median 6-year follow-up, representing permanent quality-of-life impairment 4.

Gastrointestinal Toxicity

Notably, smoking does not appear to increase gastrointestinal toxicity rates in most studies 2, 3, distinguishing bowel/sphincter dysfunction as the primary concern.

Quality of Life Impact

Beyond specific toxicities, smoking demonstrates concurrent and longitudinal associations with poorer health-related quality of life in prostate cancer survivors 5:

• Worse general health, mental health, and physical functioning (all p < 0.05)
• Clear dose-response pattern: smoking ≥1 pack/day produces the greatest declines
• Effects persist throughout 5-year survivorship period

Mechanistic Considerations

The biological rationale for these outcomes includes:

• Vascular injury and tissue hypoxia from smoking compounds radiation-induced vascular damage 4
• Impaired tissue oxygenation reduces radiosensitivity and treatment efficacy
• Fibrosis promotion from both smoking and radiation creates synergistic tissue damage
• Immune suppression from smoking may compromise tumor control 1

Clinical Implications and Recommendations

Timing of Cessation

While the NCCN guidelines don't specify optimal cessation timing for prostate cancer specifically, evidence from other cancers suggests at least 4 weeks before treatment reduces complications 1. However, for prostate radiotherapy:

• Immediate cessation is critical given that current smoking status (not just history) drives the worst outcomes
• Former smokers retain elevated toxicity risk, emphasizing that earlier cessation is always better
• Cessation should continue throughout treatment and survivorship to maximize benefit

Counseling Approach

Oncologists must explicitly communicate to each patient that smoking during radiotherapy will:

1. Reduce their chance of cure by approximately 40%
2. More than double their risk of cancer spreading
3. Double their risk of dying from prostate cancer
4. Substantially increase severe, permanent bowel and urinary complications

This is not a generic "smoking is bad" message—these are specific, quantifiable risks directly related to their cancer treatment 6.

Integration into Practice

• Structured smoking assessment should be a core component of prostate cancer survivorship care 5
• Smoking cessation programs should be offered before initiating radiotherapy 2
• Smoking status should be monitored throughout treatment and follow-up
• Consider this a teachable moment when patients may be most motivated to quit 6

Important Caveats

One contradictory study in a predominantly minority population found no association between smoking and outcomes or toxicity 7. However, this represents a single study with shorter follow-up (76 months median) and smaller sample size, contradicting multiple larger studies and NCCN guideline consensus. The weight of evidence strongly supports the harmful effects of smoking.

Comorbidities matter: Patients with cardiovascular disease, COPD, or Charlson comorbidity index ≥1 face additional risks for second primary cancers after radiotherapy 8, making smoking cessation even more critical in these populations.

1, 6, 2, 3, 4, 5